Intech Biopharm Corporation (TPEX:6461)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
23.90
+2.15 (9.89%)
At close: Feb 26, 2026
-8.43%
Market Cap 3.89B
Revenue (ttm) 113.85M
Net Income (ttm) -370.35M
Shares Out 162.92M
EPS (ttm) -2.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,119,994
Average Volume 565,451
Open 23.90
Previous Close 21.75
Day's Range 23.85 - 23.90
52-Week Range 14.10 - 26.00
Beta -0.05
RSI 65.37
Earnings Date Mar 12, 2026

About Intech Biopharm

Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. It owns iLEF (inhaled low ethanol formulation), a metered dose inhaler platform for treating asthma and COPD; and dry powder inhaler, a product comprises of blisters and capsules. The company offers its products under the SYN006, SYN010, SYN007, Synflutide, Duasma, Synvent, and SYN011 names. Intech Biopharm Corporation was founded in 2010 and is headquartered in Taipei, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 90
Stock Exchange Taipei Exchange
Ticker Symbol 6461
Full Company Profile

Financial Performance

In 2024, Intech Biopharm's revenue was 39.78 million, an increase of 53.90% compared to the previous year's 25.85 million. Losses were -368.21 million, 8.94% more than in 2023.

Financial Statements

News

There is no news available yet.